Close

ArQule's (ARQL) Tivantinib Still Has Potential in HCC

January 11, 2013 1:37 PM EST Send to a Friend
Shares of ArQule Inc. (Nasdaq: ARQL) declined Friday morning after it announced disappointing top-line results from a Phase 2 signal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login